Consensus Viking Therapeutics, Inc.

Equities

VKTX

US92686J1060

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
74.31 USD +7.91% Intraday chart for Viking Therapeutics, Inc. +17.17% +299.30%

Evolution of the average Target Price on Viking Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

5874743ad6c01fb717e33830214.WuHK_oHrRCY0UQIrG7pv5ku4ZJbn6x5hHGs1SAy2lh4.Dqyt09WyFl51GEFTSY1angjKVfK2r2QPbgVlLTnmz1Uqg4yo-9wSaFAHbQ~d97e10625257d7fce36421d626f3ee0a
Oppenheimer Adjusts Viking Therapeutics Price Target to $138 From $116, Maintains Outperform Rating MT
Stifel Adjusts Viking Therapeutics Price Target to $95 From $80, Maintains Buy Rating MT
BTIG Raises Price Target on Viking Therapeutics to $100 From $86, Keeps Buy Rating MT
Jefferies Starts Viking Therapeutics With Buy Rating, $110 Price Target MT
Oppenheimer Adjusts Viking Therapeutics Price Target to $116 From $46, Maintains Outperform Rating MT
HC Wainwright Raises Price Target on Viking Therapeutics to $90 From $33, Keeps Buy Rating MT
Stifel Adjusts Price Target on Viking Therapeutics to $35 From $30, Maintains Buy Rating MT
Oppenheimer Adjusts Viking Therapeutics Price Target to $46 From $40, Maintains Outperform Rating MT
Health Care Down on Rotation to Rate-Sensitive Sectors -- Health Care Roundup DJ
Raymond James Adjusts Viking Therapeutics Price Target to $37 From $35, Maintains Outperform Rating MT
Stifel Adjusts Viking Therapeutics' Price Target to $30 From $25, Keeps Buy Rating MT
BTIG Adjusts Viking Therapeutics' Price Target to $36 From $31, Keeps Buy Rating MT
Roth MKM Adjusts Price Target on Viking Therapeutics to $24 From $19, Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on Viking Therapeutics to $33 From $21, Maintains Buy Rating MT
Oppenheimer Adjusts Viking Therapeutics Price Target to $35 From $30, Maintains Outperform Rating MT
BTIG Research Adjusts Viking Therapeutics Price Target to $31 From $20, Maintains Buy Rating MT
Raymond James Adjusts Viking Therapeutics Price Target to $35 From $12, Maintains Outperform Rating MT
Stifel Nicolaus Adjusts Viking Therapeutics Price Target to $25 From $22, Maintains Buy Rating MT
Stifel Initiates Viking Therapeutics at Buy With $22 Price Target MT
Raymond James Adjusts Price Target on Viking Therapeutics to $12 From $11, Maintains Outperform Rating MT
Oppenheimer Adjusts Viking Therapeutics' Price Target to $17 From $15, Maintains Outperform Rating MT
Oppenheimer Adjusts Viking Therapeutics Price Target to $15 From $13, Maintains Outperform Rating MT
Oppenheimer Adjusts Viking Therapeutics Price Target to $13 From $10, Maintains Outperform Rating MT
Maxim Group Adjusts Viking Therapeutics Price Target to $15 From $10, Maintains Buy Rating MT
Oppenheimer Adjusts Viking Therapeutics Price Target to $10 From $12, Maintains Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
74.31 USD
Average target price
108.4 USD
Spread / Average Target
+45.93%
High Price Target
138 USD
Spread / Highest target
+85.71%
Low Price Target
54.86 USD
Spread / Lowest Target
-26.17%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Viking Therapeutics, Inc.

Oppenheimer
Stifel Nicolaus
BTIG
Jefferies & Co.
HC Wainwright
Raymond James
Roth MKM
Maxim
SVB Leerink
Vining Sparks
  1. Stock Market
  2. Equities
  3. VKTX Stock
  4. Consensus Viking Therapeutics, Inc.